Latest News and Press Releases

ASTRAZENECA LICENSES ZURAMPIC TO GRÜNENTHAL GMBH IN EUROPE AND LATIN AMERICA Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout AstraZeneca today...

POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR ADULTS WITH TYPE-2 DIABETES AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of...

AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic...

27 May 2016 AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 23 May 2016, the interest of Luke Miels, a person discharging managerial responsibilities, in AstraZeneca...

ASTRAZENECA PROVIDES TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL IN ADVANCED GASTRIC CANCER 18 May 2016 AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel...

ASTRAZENECA ANNOUNCES POSITIVE RESULTS FROM BENRALIZUMAB PHASE III PROGRAMME IN SEVERE ASTHMA Benralizumab first AstraZeneca respiratory biologic to complete Phase III 17 May 2016 AstraZeneca today...

SELUMETINIB granted Orphan Drug Designation in the US for ADJUVANT treatment of Differentiated thyroid cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Publication of Final Terms in relation to the...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION AstraZeneca launches and prices bond issues of...